AFFINITY OF R-396, AN NK-2 TACHYKININ RECEPTOR ANTAGONIST, FOR NK-2 RECEPTORS IN PREPARATIONS FROM DIFFERENT SPECIES

被引:19
作者
MAGGI, CA
PATACCHINI, R
ASTOLFI, M
ROVERO, P
GIACHETTI, A
VANGIERSBERGEN, PLM
机构
[1] MARION MERRELL DOW RES INST,CINCINNATI,OH
[2] UNIV CINCINNATI,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45221
[3] A MENARINI PHARMACEUT DEPT CHEM,FLORENCE,ITALY
[4] MENARINI SUD,ROME,ITALY
关键词
D O I
10.1016/0143-4179(92)90061-Z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We have assessed the affinity of R 396 (Ac. Leu-Asp-Gln-Trp-Phe-Gly NH2) in a number of NK-2 tachykinin receptor bearing-tissues from several species. The cyclic analog of R 396, (MEN 10354) was less potent and selective than the linear hexapeptide at NK-2 tachykinin receptors subtypes in the rabbit pulmonary artery and hamster trachea. The affinity of R 396, as measured by a smooth muscle contraction assay and a radioligand binding assay, was higher (about 10 fold) for NK-2 receptors expressed in hamster tissues (urinary bladder, stomach and trachea) than in rat tissues (urinary bladder, vas deferens, colon and stomach) and a further drop in affinity was observed in bovine tissues (urinary bladder and stomach) or rabbit bronchus. The results are discussed in relation to the proposed existence of NK-2 receptor subtypes and raise the question of the existence of species-related differences as compared to the existence of true receptor subtypes.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 21 条
[11]   ACTIVITY OF SPANTIDE-I AND SPANTIDE-II AT VARIOUS TACHYKININ RECEPTORS AND NK-2 TACHYKININ RECEPTOR SUBTYPES [J].
MAGGI, CA ;
PATACCHINI, R ;
FENG, DM ;
FOLKERS, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 199 (01) :127-129
[12]   COMPETITIVE ANTAGONISTS DISCRIMINATE BETWEEN NK2 TACHYKININ RECEPTOR SUBTYPES [J].
MAGGI, CA ;
PATACCHINI, R ;
GIULIANI, S ;
ROVERO, P ;
DION, S ;
REGOLI, D ;
GIACHETTI, A ;
MELI, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 100 (03) :588-592
[13]  
MAGGI CA, 1991, IN PRESS ANN NY ACAD
[14]   CDNA CLONING OF BOVINE SUBSTANCE-K RECEPTOR THROUGH OOCYTE EXPRESSION SYSTEM [J].
MASU, Y ;
NAKAYAMA, K ;
TAMAKI, H ;
HARADA, Y ;
KUNO, M ;
NAKANISHI, S .
NATURE, 1987, 329 (6142) :836-838
[15]   PHARMACOLOGICAL SPECIFICITY OF SYNTHETIC PEPTIDES AS ANTAGONISTS AT TACHYKININ RECEPTORS [J].
MCKNIGHT, AT ;
MAGUIRE, JJ ;
WILLIAMS, BJ ;
FOSTER, AC ;
TRIDGETT, R ;
IVERSEN, LL .
REGULATORY PEPTIDES, 1988, 22 (1-2) :127-127
[16]   FURTHER EVIDENCE FOR THE EXISTENCE OF NK2 TACHYKININ RECEPTOR SUBTYPES [J].
PATACCHINI, R ;
ASTOLFI, M ;
QUARTARA, L ;
ROVERO, P ;
GIACHETTI, A ;
MAGGI, CA .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (01) :91-96
[17]  
PATACCHINI R, 1989, J PHARMACOL EXP THER, V250, P678
[18]  
REGOLI D, 1987, SUBSTANCE P NEUROKIN, P99
[19]   MOLECULAR CHARACTERIZATION OF RAT SUBSTANCE-K RECEPTOR AND ITS MESSENGER-RNAS [J].
SASAI, Y ;
NAKANISHI, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (02) :695-702
[20]   CHARACTERIZATION OF A TACHYKININ PEPTIDE NK2 RECEPTOR TRANSFECTED INTO MURINE FIBROBLAST B82 CELLS [J].
VANGIERSBERGEN, PLM ;
SHATZER, SA ;
HENDERSON, AK ;
LAI, J ;
NAKANISHI, S ;
YAMAMURA, HI ;
BUCK, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (05) :1661-1665